Extravascular administration of interferon alfa-n3 increases serum exposure and 2-5(A) synthetase activity

Marc Sturgill, A. Rashidbaigi, M. J. Liao, X. X. Zhao, Ji Hua, R. Trout, J. R. Knill, K. W. Grasing

Research output: Contribution to journalArticle

3 Scopus citations


The objective of this study was to evaluate the pharmacokinetics, pharmacodynamic response, and safety of single intravenous (IV), intramuscular (IM), and subcutaneous (SQ) doses of interferon alfa-n3. Six healthy adults received 10 million units of IV, IM, and SQ interferon alfa-n3 in a randomized three-period crossover fashion. Serum interferon alfa-n3 concentrations and 2'-5'-oligoadenylate synthetase (2-5[A] synthetase) activity in peripheral blood mononuclear cells were determined after each dose. Extravascular administration significantly increased mean serum interferon alfa-n3 AUC values (1152 ± 214, 944 ± 209, and 576 ± 188 U·h/mL, p < 0.001, with SQ, IM, and IV administration, respectively) and 2-5(A) synthetase activity at 36 and 48 hours after dosing. Mild to moderate flu-like symptoms were reported by all 6 subjects, with no route-related difference in type or incidence. Interferon alfa-n3 is generally well tolerated by the IV, IM, and SQ routes, with IM and SQ administration maximizing serum exposure and 2-5(A) synthetase activity. (C) 2000 the American College of Clinical Pharmacology.

Original languageEnglish (US)
Pages (from-to)606-615
Number of pages10
JournalJournal of Clinical Pharmacology
Issue number6
StatePublished - Jan 1 2000

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Extravascular administration of interferon alfa-n3 increases serum exposure and 2-5(A) synthetase activity'. Together they form a unique fingerprint.

  • Cite this